Jie Liu

Jie Liu


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2026 in International Journal of Pharmaceutics: X
Verified
Journal Article
Open access
YCYibin Cai
Yibin Cai
JLJiayin Li
Jiayin Li
SCShenyu Chen
Shenyu Chen
HZHui Zhang
Hui Zhang
JTJie Tan
Jie Tan
JLJie Liu
Jie Liu
Liver fibrosis is a dynamic pathological process characterized by excessive extracellular matrix (ECM) deposition, primarily driven by the activation of hepatic stellate cells (HSCs). Recent advances in liver fibrosis research have identified critical pathways, such as oxidative stress, inflammation and transforming growth factor-β (TGF-β) signaling, which drive disease progression. Concurrently, innovative drug delivery systems (e.g., liposomes, micelles and nanocrystals) have emerged to enhance therapeutic efficacy and targeting. These systems enable precise delivery of antifibrotic agents to HSCs or fibrotic tissues, minimizing off-target effects and improving pharmacokinetic profiles. This review summarizes current understanding of liver fibrosis pathogenesis and recent advances in drug delivery strategies, highlighting clinical transformation opportunities and future research directions. Combining molecular insights with advanced delivery technologies represents a promising avenue for developing effective antifibrotic therapies.